Pertinax Pharma appoint Paul Williams as Business Development Manager
To help drive expansion into new global markets, Pertinax Pharma has bolstered its commercial team with the appointment of Paul Williams as Business Development Manager.
Currently undertaking his MBA Global at the University of Derby, Paul is an accomplished international sales professional who joins Pertinax having held senior positions at Scapa Healthcare and BBI Solutions.
Paul comments on his new role: “I simply couldn’t resist being part of the Pertinax team orchestrating the company’s business development activity. The patented technology has significant market potential in multiple sectors. We are already in talks with several manufacturers and over the next few months, we expect to have applications of Pertinax® in development for use in advanced wound care, veterinary and dental products.”
Working alongside Chairman Nigel Brooksby, Paul will execute the commercial strategy to develop and nurture the Pertinax client base.
Dr Michele Barbour, Chief Executive Officer, comments on Paul’s appointment: “We’re really happy to have Paul on board. He’s got an excellent track record of winning new business and comes with an extensive network of industry contacts, his skills and relevant experience of selling critical raw materials and contract development will be invaluable as we drive the business forward.
About Pertinax Pharma
Pertinax Pharma Ltd – originally a spin out from the university of Bristol – was established in April 2015 to commercialise its proprietary and patented Pertinax® technology. The antimicrobial material has wide ranging potential application across wound care, dentistry, medical device, veterinary and broader markets. Pertinax provides controlled and sustained release of chlorhexidine (CHX) – overcoming the short duration of antimicrobial activity of conventional CHX products. The antimicrobial can be formulated to persist for days, weeks, months or years – depending on the application. Pertinax requires lower quantities of CHX – with continuous antimicrobial function provided by less frequent applications – and it also exhibits lower cytotoxicity than equivalent concentrations of conventional CHX.